SI2977057T1 - Izolirana rekombinantna humana N-glikozilirana lizosomska kisla lipaza - Google Patents

Izolirana rekombinantna humana N-glikozilirana lizosomska kisla lipaza

Info

Publication number: SI2977057T1
Authority: SI; Slovenia
Prior art keywords: recombinant human; isolated recombinant; acid lipase; lysosomal acid; glycosylated lysosomal
Prior art date: 2010-09-09

Application number

SI201131841T

Other languages

English (en)

Inventor

Anthony Quinn

Original Assignee

Alexion Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-09

Filing date

2011-09-09

Publication date

2020-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2977057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-23 Priority claimed from PCT/US2011/033699 external-priority patent/WO2011133960A2/en

2011-09-09 Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.

2020-03-31 Publication of SI2977057T1 publication Critical patent/SI2977057T1/sl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01013—Sterol esterase (3.1.1.13)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

SI201131841T 2010-09-09 2011-09-09 Izolirana rekombinantna humana N-glikozilirana lizosomska kisla lipaza SI2977057T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US40301110P	2010-09-09	2010-09-09
US45601410P	2010-10-29	2010-10-29
US201161432372P	2011-01-13	2011-01-13
PCT/US2011/033699 WO2011133960A2 (en)	2010-04-23	2011-04-23	Lysosomal storage disease enzyme
EP14200334.2A EP2977057B1 (en)	2010-09-09	2011-09-09	Isolated recombinant human n-glycosylated lysosomal acid lipase

Publications (1)

Publication Number	Publication Date
SI2977057T1 true SI2977057T1 (sl)	2020-03-31

Family

ID=45806910

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201131841T SI2977057T1 (sl)	2010-09-09	2011-09-09	Izolirana rekombinantna humana N-glikozilirana lizosomska kisla lipaza
SI201130465T SI2613798T2 (sl)	2010-09-09	2011-09-09	Uporaba lizosomske kisle lipaze za zdravljenje pomanjkanja lizosomske kisle lipaze pri pacientih

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201130465T SI2613798T2 (sl)	2010-09-09	2011-09-09	Uporaba lizosomske kisle lipaze za zdravljenje pomanjkanja lizosomske kisle lipaze pri pacientih

Country Status (30)

Country	Link
US (5)	US8663631B2 (sl)
EP (3)	EP2977057B1 (sl)
JP (3)	JP5693728B2 (sl)
KR (1)	KR20150038636A (sl)
CN (2)	CN103200958A (sl)
AR (1)	AR082953A1 (sl)
AU (1)	AU2011314293B2 (sl)
BR (2)	BR112013005673B1 (sl)
CA (2)	CA3209456A1 (sl)
CL (1)	CL2013000664A1 (sl)
CO (1)	CO6710913A2 (sl)
CY (1)	CY1116544T1 (sl)
DK (2)	DK2613798T4 (sl)
ES (2)	ES2535605T5 (sl)
HK (2)	HK1220907A1 (sl)
HR (1)	HRP20150438T1 (sl)
HU (1)	HUE048688T2 (sl)
IL (2)	IL225095A (sl)
ME (1)	ME02062B (sl)
MX (2)	MX365007B (sl)
NZ (3)	NZ715014A (sl)
PL (2)	PL2977057T3 (sl)
PT (2)	PT2977057T (sl)
RS (1)	RS53947B1 (sl)
RU (1)	RU2550961C2 (sl)
SG (2)	SG188456A1 (sl)
SI (2)	SI2977057T1 (sl)
SM (1)	SMT201500108B (sl)
TW (1)	TWI482625B (sl)
WO (1)	WO2012050695A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001056596A1 (en) *	2000-02-04	2001-08-09	Children's Hospital Research Foundation	Use of lysosomal acid lipase for treating atherosclerosis and related diseases
US20090297496A1 (en) *	2005-09-08	2009-12-03	Childrens Hospital Medical Center	Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP2561069B1 (en)	2010-04-23	2017-03-08	Alexion Pharmaceuticals, Inc.	Lysosomal storage disease enzyme
BR112013005673B1 (pt) *	2010-09-09	2020-12-15	Alexion Pharmaceuticals, Inc	Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal
WO2012112681A1 (en) *	2011-02-15	2012-08-23	Shire Human Genetic Therapies, Inc.	Methods for treating lysosomal acid lipase deficiency
EP2766477B1 (en)	2011-10-12	2018-09-26	Alexion Pharmaceuticals, Inc.	Recombinant human naglu protein and uses thereof
WO2013131014A1 (en) *	2012-03-02	2013-09-06	Synageva Biopharma Corp.	Truncated lysosomal acid lipase
CN106885910B (zh) *	2015-12-15	2018-12-21	上海吉涛生物科技有限公司	肿瘤易感微环境检测装置及试剂盒
US11235036B2 (en)	2016-06-17	2022-02-01	Alexion Pharmaceuticals, Inc.	Lysosomal acid lipase deficiency compositions and methods
US11155794B2 (en)	2016-08-23	2021-10-26	Alexion Pharmaceuticals, Inc.	Method of purifying a heterologous protein from an egg white
US10633705B2 (en)	2016-10-14	2020-04-28	Alexion Pharmaceuticals, Inc.	N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US11396499B2 (en)	2018-12-12	2022-07-26	University Of Washington	Lysosomal acid lipase assay
WO2021117122A1 (ja) *	2019-12-10	2021-06-17	株式会社リボルナバイオサイエンス	ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9001985D0 (sv)	1990-06-01	1990-06-01	Astra Ab	New chemical products
AU1580292A (en)	1991-03-13	1992-10-21	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0952841A4 (en)	1994-08-05	2000-11-02	Molecular Structural Biotechno	DIRECTED BIOMOLECULAR COMPLEXES
US6118045A (en)	1995-08-02	2000-09-12	Pharming B.V.	Lysosomal proteins produced in the milk of transgenic animals
WO1997010353A1 (en)	1995-09-14	1997-03-20	Virginia Tech Intellectual Property, Inc.	Production of lysosomal enzymes in plant-based expression systems
ES2458292T3 (es)	1996-09-13	2014-04-30	Shire Human Genetic Therapies, Inc.	Producción de alfa-galactosidasa A humana
CA2305768A1 (en)	1997-10-29	2000-02-24	Genzyme Corporation	Compositions and methods for treating lysosomal storage disease
US20030166132A1 (en)	1998-08-26	2003-09-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000034451A1 (en)	1998-12-07	2000-06-15	Pharming Intellectual Property B.V.	Treatment of pompe's disease
US7033780B1 (en)	1999-06-14	2006-04-25	Millennium Pharmaceuticals, Inc.	Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en)	1999-08-05	2011-04-19	Regents Of The University Of Minnesota	MAPC administration for the treatment of lysosomal storage disorders
US6642038B1 (en)	1999-09-14	2003-11-04	Genzyme Glycobiology Research Institute, Inc.	GlcNAc phosphotransferase of the lysosomal targeting pathway
WO2001056596A1 (en)	2000-02-04	2001-08-09	Children's Hospital Research Foundation	Use of lysosomal acid lipase for treating atherosclerosis and related diseases
AU2001269923A1 (en)	2000-06-19	2002-01-02	Genzyme Corporation	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040038365A1 (en)	2000-10-31	2004-02-26	Yonghong Xiao	Regulation of human lysosomal acid lipase
US20030064437A1 (en)	2000-11-15	2003-04-03	Nick Wan	Expression system for recombinant proteins
US20020193303A1 (en)	2001-01-25	2002-12-19	Millennium Pharmaceuticals, Inc.	58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en)	2001-12-21	2004-10-05	Genzyme Glycobiology Research Institute, Inc.	Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20050181474A1 (en)	2002-01-30	2005-08-18	Frank J. Giordano	Transport peptides and uses therefor
EP1495328B1 (en)	2002-04-16	2014-06-18	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	A marker for measuring liver cirrhosis
CA2499188A1 (en)	2002-09-27	2004-04-08	Cold Spring Harbor Laboratory	Cell-based rna interference and related methods and compositions
US20050208090A1 (en)	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
US20070270364A1 (en)	2004-06-15	2007-11-22	Mayo Foundation For Medical Education And Research	Helicases
BRPI0514409A (pt)	2004-08-19	2008-06-10	Biogen Idec Inc	redobra de proteìnas da famìlia de fator de crescimento transformante beta
US20070270367A1 (en)	2005-05-18	2007-11-22	University Of Kentucky Research Foundation	Rybozyme-catalyzed insertion of targeted sequences into RNA
US8124732B2 (en) *	2005-06-24	2012-02-28	Synageva Biopharma Corp.	Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20090297496A1 (en) *	2005-09-08	2009-12-03	Childrens Hospital Medical Center	Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl)	2005-09-21	2007-04-02	Instytut Farmaceutyczny	Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US7524626B2 (en)	2005-10-05	2009-04-28	Synageva Biopharma Corp.	Rapid production of high titer virus
AR059089A1 (es) *	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en)	2006-05-18	2007-11-22	Cullen David P	Roof safety system
US8748567B2 (en)	2006-05-22	2014-06-10	Children's Medical Center Corporation	Method for delivery across the blood brain barrier
WO2007137303A2 (en)	2006-05-24	2007-11-29	Myelin Repair Foundation, Inc.	Permeability of blood-brain barrier
US8143265B2 (en)	2007-04-16	2012-03-27	Meharry Medical College	Method of treating atherosclerosis
WO2008131431A2 (en)	2007-04-23	2008-10-30	St. Louis University	Modulation of blood brain barrier protein expression
AU2008256644B2 (en)	2007-05-24	2014-07-03	The United States Government As Represented By The Department Of Veterans Affairs	Intranuclear protein transduction through a nucleoside salvage pathway
AU2008255565B2 (en)	2007-05-31	2013-10-24	Paradigm Biopharmaceuticals Ltd	Sulphated xylans for treatment or prophylaxis of respiratory diseases
AU2008273094B2 (en)	2007-07-12	2013-05-09	Prosensa Technologies B.V.	Molecules for targeting compounds to various selected organs, tissues or tumor cells
US20100291060A1 (en)	2007-08-29	2010-11-18	Shire Human Genetic Therapies, Inc	Subcutaneous administration of alpha-galactosidase a
KR101343485B1 (ko)	2008-01-07	2013-12-20	시나게바 바이오파르마, 코포레이션	조류에서의 당화
FR2937322B1 (fr)	2008-10-22	2013-02-22	Vect Horus	Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8232073B2 (en)	2009-01-02	2012-07-31	Zacharon Pharmaceuticals, Inc.	Quantification of non-reducing end glycan residual compounds
US8183003B2 (en)	2009-01-02	2012-05-22	Zacharon Pharmaceuticals, Inc.	Polymer end group detection
CA2766614C (en)	2009-07-03	2018-06-19	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110033699A1 (en)	2009-07-23	2011-02-10	Nitto Denko Corporation	Pressure-sensitive adhesive tape
WO2011049737A1 (en)	2009-10-19	2011-04-28	Amicus Therapeutics, Inc.	Novel compositions for preventing and/or treating lysosomal storage disorders
KR101077618B1 (ko)	2009-11-13	2011-10-27	경북대학교 산학협력단	뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en)	2009-11-24	2015-08-04	Arch Cancer Therapeutics, Inc.	Brain tumor targeting peptides and methods
ES2628841T3 (es)	2010-03-12	2017-08-04	Alexion Pharmaceuticals, Inc.	Proteínas de fusión npp1
EP2561069B1 (en) *	2010-04-23	2017-03-08	Alexion Pharmaceuticals, Inc.	Lysosomal storage disease enzyme
US20150030582A1 (en)	2010-04-23	2015-01-29	Synageva Biopharma Corp.	Lysosomal Storage Disease Enzyme
BR112013005673B1 (pt) *	2010-09-09	2020-12-15	Alexion Pharmaceuticals, Inc	Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal
WO2012112681A1 (en)	2011-02-15	2012-08-23	Shire Human Genetic Therapies, Inc.	Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en)	2011-02-15	2012-08-23	Children's Hospital Medical Center	Methods for treating lysosomal acid lipase deficiency
US8865881B2 (en)	2011-02-22	2014-10-21	California Institute Of Technology	Delivery of proteins using adeno-associated virus (AAV) vectors
WO2012159052A2 (en)	2011-05-18	2012-11-22	Children's Hospital Medical Center	Targeted delivery of proteins across the blood brain barrier
US9155784B2 (en)	2011-06-20	2015-10-13	Icahn School Of Medicine At Mount Sinai	Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en)	2011-06-22	2012-12-27	Alnylam Pharmaceuticals, Inc.	Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en)	2011-07-28	2013-01-31	Abb Inc.	Current sensor
MX351565B (es)	2011-08-03	2017-10-19	Phoenix Tissue Repair Inc	Colageno 7 y metodos relacionados.
EP2766477B1 (en)	2011-10-12	2018-09-26	Alexion Pharmaceuticals, Inc.	Recombinant human naglu protein and uses thereof

2011
- 2011-09-09 BR BR112013005673-8A patent/BR112013005673B1/pt active IP Right Grant
- 2011-09-09 DK DK11758644.6T patent/DK2613798T4/en active
- 2011-09-09 NZ NZ715014A patent/NZ715014A/en unknown
- 2011-09-09 HU HUE14200334A patent/HUE048688T2/hu unknown
- 2011-09-09 PT PT142003342T patent/PT2977057T/pt unknown
- 2011-09-09 CA CA3209456A patent/CA3209456A1/en active Pending
- 2011-09-09 KR KR20157006132A patent/KR20150038636A/ko not_active Application Discontinuation
- 2011-09-09 SI SI201131841T patent/SI2977057T1/sl unknown
- 2011-09-09 EP EP14200334.2A patent/EP2977057B1/en active Active
- 2011-09-09 MX MX2015002597A patent/MX365007B/es unknown
- 2011-09-09 ME MEP-2015-41A patent/ME02062B/me unknown
- 2011-09-09 SG SG2013017181A patent/SG188456A1/en unknown
- 2011-09-09 AU AU2011314293A patent/AU2011314293B2/en active Active
- 2011-09-09 MX MX2013002704A patent/MX2013002704A/es active IP Right Grant
- 2011-09-09 ES ES11758644.6T patent/ES2535605T5/es active Active
- 2011-09-09 JP JP2013528353A patent/JP5693728B2/ja active Active
- 2011-09-09 WO PCT/US2011/051096 patent/WO2012050695A1/en active Application Filing
- 2011-09-09 US US13/229,558 patent/US8663631B2/en active Active
- 2011-09-09 NZ NZ608292A patent/NZ608292A/en not_active IP Right Cessation
- 2011-09-09 SI SI201130465T patent/SI2613798T2/sl unknown
- 2011-09-09 NZ NZ700824A patent/NZ700824A/en not_active IP Right Cessation
- 2011-09-09 RS RS20150239A patent/RS53947B1/en unknown
- 2011-09-09 DK DK14200334.2T patent/DK2977057T3/da active
- 2011-09-09 PL PL14200334T patent/PL2977057T3/pl unknown
- 2011-09-09 PT PT117586446T patent/PT2613798E/pt unknown
- 2011-09-09 TW TW100132633A patent/TWI482625B/zh not_active IP Right Cessation
- 2011-09-09 RU RU2013110491/15A patent/RU2550961C2/ru active
- 2011-09-09 BR BR122019021757-2A patent/BR122019021757B1/pt active IP Right Grant
- 2011-09-09 CA CA2810999A patent/CA2810999C/en active Active
- 2011-09-09 CN CN201180053951XA patent/CN103200958A/zh active Pending
- 2011-09-09 AR ARP110103302A patent/AR082953A1/es unknown
- 2011-09-09 PL PL11758644T patent/PL2613798T5/pl unknown
- 2011-09-09 EP EP11758644.6A patent/EP2613798B2/en active Active
- 2011-09-09 SG SG10201507199UA patent/SG10201507199UA/en unknown
- 2011-09-09 ES ES14200334T patent/ES2769836T3/es active Active
- 2011-09-09 EP EP19199414.4A patent/EP3650039A1/en active Pending
- 2011-09-09 CN CN201511021370.4A patent/CN105457018A/zh active Pending
2013
- 2013-03-07 IL IL225095A patent/IL225095A/en active IP Right Grant
- 2013-03-08 CL CL2013000664A patent/CL2013000664A1/es unknown
- 2013-04-09 CO CO13092089A patent/CO6710913A2/es unknown
- 2013-10-30 HK HK16109058.2A patent/HK1220907A1/zh unknown
- 2013-12-10 US US14/102,000 patent/US20140348752A1/en not_active Abandoned
2014
- 2014-12-04 JP JP2014245814A patent/JP6156882B2/ja active Active
2015
- 2015-04-21 CY CY20151100369T patent/CY1116544T1/el unknown
- 2015-04-21 HR HRP20150438TT patent/HRP20150438T1/hr unknown
- 2015-05-05 SM SM201500108T patent/SMT201500108B/xx unknown
- 2015-09-11 US US14/851,387 patent/US10166274B2/en active Active
2016
- 2016-03-24 HK HK16103494.7A patent/HK1215532A1/zh unknown
- 2016-04-21 IL IL245283A patent/IL245283B/en active IP Right Grant
- 2016-05-12 JP JP2016096147A patent/JP2016145257A/ja active Pending
2018
- 2018-11-14 US US16/190,878 patent/US11400141B2/en active Active
2022
- 2022-06-30 US US17/854,325 patent/US20220362350A1/en active Pending

Also Published As

Publication number	Publication date
CA2810999A1 (en)	2012-04-19
NZ715014A (en)	2018-10-26
JP2013540733A (ja)	2013-11-07
PL2613798T5 (pl)	2018-06-29
SI2613798T1 (sl)	2015-05-29
PT2977057T (pt)	2020-02-18
DK2613798T4 (en)	2018-04-16
HUE048688T2 (hu)	2020-08-28
NZ700824A (en)	2016-03-31
ES2769836T3 (es)	2020-06-29
SG188456A1 (en)	2013-04-30
CL2013000664A1 (es)	2013-10-04
SG10201507199UA (en)	2015-10-29
IL225095A (en)	2016-05-31
RU2013110491A (ru)	2014-11-10
DK2613798T3 (en)	2015-04-20
US20190282671A1 (en)	2019-09-19
EP2613798B1 (en)	2015-02-11
US20160051638A1 (en)	2016-02-25
RS53947B1 (en)	2015-08-31
NZ608292A (en)	2014-10-31
RU2550961C2 (ru)	2015-05-20
HK1220907A1 (zh)	2017-05-19
US20140348752A1 (en)	2014-11-27
JP2016145257A (ja)	2016-08-12
US20220362350A1 (en)	2022-11-17
HRP20150438T1 (hr)	2015-05-22
JP6156882B2 (ja)	2017-07-05
KR20150038636A (ko)	2015-04-08
SI2613798T2 (sl)	2018-05-31
EP3650039A1 (en)	2020-05-13
AR082953A1 (es)	2013-01-23
BR122019021757B1 (pt)	2020-12-08
ES2535605T3 (es)	2015-05-13
MX2013002704A (es)	2013-09-13
IL245283B (en)	2019-02-28
CN103200958A (zh)	2013-07-10
IL245283A0 (en)	2016-06-30
SMT201500108B (it)	2015-07-09
BR112013005673A2 (pt)	2017-09-19
DK2977057T3 (da)	2020-02-10
US11400141B2 (en)	2022-08-02
US10166274B2 (en)	2019-01-01
EP2613798B2 (en)	2018-01-24
CY1116544T1 (el)	2018-03-07
ES2535605T5 (es)	2018-04-30
CN105457018A (zh)	2016-04-06
PL2613798T3 (pl)	2015-07-31
AU2011314293B2 (en)	2015-06-04
HK1215532A1 (zh)	2016-09-02
BR112013005673B1 (pt)	2020-12-15
AU2011314293A1 (en)	2013-04-04
TWI482625B (zh)	2015-05-01
EP2977057B1 (en)	2019-11-06
EP2613798A1 (en)	2013-07-17
PL2977057T3 (pl)	2020-06-01
CA2810999C (en)	2023-10-03
US20120064055A1 (en)	2012-03-15
US8663631B2 (en)	2014-03-04
CO6710913A2 (es)	2013-07-15
TW201225971A (en)	2012-07-01
JP5693728B2 (ja)	2015-04-01
WO2012050695A1 (en)	2012-04-19
PT2613798E (pt)	2015-06-02
EP2977057A1 (en)	2016-01-27
CA3209456A1 (en)	2012-04-19
JP2015052014A (ja)	2015-03-19
ME02062B (me)	2015-05-20
MX365007B (es)	2019-05-20

Publication	Publication Date	Title
HK1215532A1 (zh)	2016-09-02	使用溶酶體酸性脂肪酶來治療患者的溶酶體酸性脂肪酶缺乏
IL240098A (en)	2017-10-31	Disinfectant containing digestive enzymes
PL2553090T3 (pl)	2019-08-30	Termostabilne warianty fitazy
EP2566371A4 (en)	2013-10-30	ACTIVE MATTRESS TENSIONER
ZA201209561B (en)	2016-10-26	Compositions and methods related to protein a (spa) variants
PL2637710T3 (pl)	2017-10-31	Preparaty na bazie kwasu hialuronowego
GB201012446D0 (en)	2010-09-08	Medico-surgical assemblies
EP2493471A4 (en)	2013-05-01	NEW GASTRO-RESISTANT POLYTHERAPY
EP2475376A4 (en)	2013-05-22	FORMULATIONS FOR LYSOSOMAL ENZYMES
EP2422837A4 (en)	2012-11-28	MEDICAL CONNECTOR STRUCTURE
GB201007384D0 (en)	2010-06-16	Enzymes
GB201709797D0 (en)	2017-08-02	Novel parasite therapy
EP2612913A4 (en)	2014-03-26	NEW HYDROLASEPROTEINS
EP2547331A4 (en)	2014-04-30	GASTRO-RESISTANT PHARMACEUTICAL COMPOSITIONS BASED ON ENZYMES
PT2391382E (pt)	2014-08-22	Preparado farmacêutico contendo lipase de origem bacteriana
EP2600843A4 (en)	2014-01-15	THERAPEUTIC PROTEIN COMPOSITIONS WITH IMPROVED IMMUNOGENICITY AND / OR ENHANCED EFFICACY
HK1173185A1 (zh)	2013-05-10	增强的肌醇六磷酸酶變體
EP2557088A4 (en)	2014-02-12	PHYSIOLOGICALLY ACTIVE PEPTIDES
ZA201202808B (en)	2013-09-25	Cloning, expression and use of acid phospholipases
EP2558506A4 (en)	2013-08-14	GEWEBEANZIELUNG
PL2359816T3 (pl)	2017-04-28	Formulacje aripiprazolu
GB201105987D0 (en)	2011-05-18	Enzymes
EP2448958A4 (en)	2013-11-06	PEPTIDES OF HUMAN MILK
EP2820032A4 (en)	2015-11-25	TRUNCATED LYSOSOMAL ACID LIPASE
IL211839A0 (en)	2011-06-30	Improved processing of recombinant human g-csf